Welcome to our dedicated page for Navidea Biopharm news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharm stock.
Navidea Biopharmaceuticals, Inc. (NAVB) is a biopharmaceutical company that describes its focus as the development of precision immunodiagnostic agents and immunotherapeutics built on its proprietary Manocept platform. Company news frequently highlights developments related to this platform, including clinical research involving Tc99m tilmanocept, which Navidea identifies as the first product developed and commercialized from Manocept.
News releases from Navidea cover a range of topics that are relevant to investors, creditors, and other stakeholders. These include updates on clinical programs, such as exploratory analyses in rheumatoid arthritis trials using Tc99m tilmanocept imaging, as well as shifts in focus toward therapeutic assets. Corporate strategy communications often reference the company’s Fix, Fund, Propel framework, which Navidea links to operational changes, financing activities, and efforts to advance its technology toward potential market applications.
Navidea’s news flow also includes significant corporate and capital structure events. Examples disclosed by the company include the NYSE American’s decision to suspend trading and initiate delisting proceedings for its common stock, the transition to trading on over-the-counter markets, the adoption and extension of a Section 382 Rights Plan aimed at protecting tax attributes, and the filing of Form 15 to deregister its securities and suspend SEC reporting obligations.
More recently, Navidea announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the U.S. Bankruptcy Code, stating that the process is intended to support an orderly restructuring of its financial obligations while continuing limited operations. Visitors to this news page can review these types of announcements to understand how Navidea describes its business focus, technology platform, strategic framework, and material corporate events over time.
Summary not available.
Summary not available.
Summary not available.
Navidea Biopharmaceuticals has signed an Asset Purchase Agreement with Meilleur Technologies for the acquisition of assets related to NAV4694, a beta-amyloid imaging agent targeting Alzheimer's disease. Meilleur will pay $750,000, comprising a $250,000 upfront payment and $500,000 due within 60 days, with potential future milestone payments based on sales and regulatory achievements. The NAV4694 imaging agent is currently in clinical trials and aims to improve early diagnosis of Alzheimer's. This partnership will enable Navidea to enhance liquidity and focus on growth while Meilleur aims to advance brain health technologies. The ongoing Phase 2b and Phase 3 trials for NAV4694 may provide important developments in Alzheimer's diagnostics.
Navidea Biopharmaceuticals (NYSE American: NAVB) has appointed G2G Ventures as executive consultants to support its aggressive growth strategy. Dr. Michael Rosol has stepped down as Chief Medical Officer after serving since 2018 to pursue other opportunities, but will assist with the transition. G2G Ventures, led by Dr. Jason Myers, aims to enhance Navidea’s business development and investor communications. The company focuses on precision immunodiagnostic agents, utilizing its Manocept platform for targeted treatments, which are critical in the company’s pipeline aimed at improving diagnostic accuracy and patient care.
Navidea Biopharmaceuticals (NYSE American: NAVB) announced its financial results for Q4 and full year 2022. Total revenues for Q4 were approximately $1,000, a decrease from $50,000 in Q4 2021, and $66,000 for the year, down from $532,000 in 2021. R&D expenses increased to $1.9 million in Q4 from $1.4 million and total expenses for the year were $6.0 million. Navidea reported a net loss of $3.5 million or $0.11 per share for Q4 and $17.2 million or $0.56 per share for 2022. The company continues to enroll participants in its NAV3-33 Phase 3 trial for rheumatoid arthritis and has received several patent approvals, enhancing its immunodiagnostic and immunotherapeutic initiatives.
Navidea Biopharmaceuticals (AMEX: NAVB) will host a conference call on March 21, 2023, at 5:00 p.m. EDT to discuss financial results for the fourth quarter and full year ended December 31, 2022.
Dr. Michael Rosol and Erika Eves will provide updates on recent developments and clinical progress. The call is aimed at sharing financial insights and addressing live questions from investors.
Navidea focuses on developing precision immunodiagnostic agents through its Manocept platform, enhancing diagnostic accuracy and treatment targeting.
Navidea Biopharmaceuticals has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application regarding compositions that alter macrophage behavior to enhance the immune response against tumors. This patent, titled “Compositions And Methods For Altering Macrophage Phenotype,” will protect critical aspects of Navidea’s cancer immunotherapy pipeline that utilizes mannosylated-amine dextrans (MADs). Positive outcomes from preclinical studies indicate potential synergies with existing cancer therapies, aiming to address significant unmet needs in oncology.
Navidea Biopharmaceuticals (NYSE American: NAVB) has filed an appeal regarding a Texas court judgment related to a case with Capital Royalty Partners II, L.P. The appeal was submitted on November 29, 2022, by Navidea and its subsidiary, Macrophage Therapeutics. This case, identified as Case No. 2018-24442-151, raises significant concerns regarding the potential future outcomes that could impact Navidea's financial condition and strategic operations. Investors are advised to remain aware of the implications of this litigation as it unfolds.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) announced the enrollment of the 50th participant in its pivotal NAV3-33 Phase 3 clinical trial, which aims to evaluate Tc99m tilmanocept imaging for predicting treatment responses in rheumatoid arthritis patients starting anti-TNFα therapy. The trial will involve 198-672 patients, targeting at least 100 responders. Previous Phase 2B data indicated a 90% accuracy in early treatment response prediction at 12 weeks. Success could significantly benefit RA patients and enhance shareholder value.